Therapeutic antibodies and uses thereof

Abstract

Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.

1 - 20 . (canceled) 
     
     
         21 . A method of treating a subject, said method comprising administering an anti-stem cell factor (SCF) antibody to a subject, wherein said anti-SCF antibody comprises:
 a light chain variable domain comprising an amino acid sequence comprising:
 a first amino acid sequence comprising the CDR1 sequence provided by amino acids 42-53 of SEQ ID NO: 4; 
 a second amino acid sequence comprising the CDR2 sequence provided by amino acids 69-79 of SEQ ID NO: 4; and 
 a third amino acid sequence comprising the CDR3 sequence provided by amino acids 112-124 of SEQ ID NO: 4; and 
   a heavy chain variable domain comprising an amino acid sequence comprising:
 a first amino acid sequence comprising the CDR1 sequence provided by amino acids 45-56 of SEQ ID NO: 2; 
 a second amino acid sequence comprising the CDR2 sequence provided by amino acids 71-86 of SEQ ID NO: 2; and 
 a third amino acid sequence comprising the CDR3 sequence provided by amino acids 119-123 of SEQ ID NO: 2. 
   
     
     
         22 . The method of  claim 21  wherein said subject has a disease that is fibrosis. 
     
     
         23 . The method of  claim 21  wherein said subject has a disease that is a tissue remodeling disease. 
     
     
         24 . The method of  claim 21  wherein said subject has a disease that is idiopathic pulmonary fibrosis, pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute respiratory distress syndrome, cystic fibrosis, peribronchial fibrosis, hypersensitivity pneumonitis, asthma, scleroderma, inflammation, liver cirrhosis, renal fibrosis, parenchymal fibrosis, endomyocardial fibrosis, mediastinal fibrosis, nodular subepidermal fibrosis, fibrous histiocytoma, fibrothorax, hepatic fibrosis, fibromyalgia, gingival fibrosis, or radiation-induced fibrosis. 
     
     
         25 . The method of  claim 21  wherein said antibody is administered into an airway of said subject. 
     
     
         26 . The method of  claim 21  wherein said antibody is administered intranasally, topically, intraocularly, parenterally, orally, intranasally, intravenously, intramuscularly, or subcutaneously. 
     
     
         27 . The method of  claim 21  wherein said antibody is provided in a physiologically appropriate solution comprising a pharmaceutically effective amount of said antibody. 
     
     
         28 . The method of  claim 21  wherein said antibody is administered in multiple doses. 
     
     
         29 . The method of  claim 21  wherein said antibody is co-administered with another compound. 
     
     
         30 . The method of  claim 21  wherein said antibody is a monoclonal antibody. 
     
     
         31 . The method of  claim 21  wherein said antibody is a humanized antibody. 
     
     
         32 . The method of  claim 21  wherein said antibody is a recombinant antibody. 
     
     
         33 . The method of  claim 21  wherein said antibody is a chimeric antibody. 
     
     
         34 . The method of  claim 21 , wherein the antibody is monovalent and comprises an Fc region. 
     
     
         35 . The method of  claim 21 , wherein the antibody is bivalent or bispecific. 
     
     
         36 . The method of  claim 21 , wherein the antibody is a Fab, Fab′-SH, Fv, scFv, or a (Fab′) 2  antibody fragment. 
     
     
         37 . The method of  claim 21 , wherein the antibody comprises a single Fab region linked to an Fc region. 
     
     
         38 . The method of  claim 21  further comprising detecting SCF in a biological sample from said subject.